Comparative Pharmacology
Head-to-head clinical analysis: INVELTYS versus OHTUVAYRE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVELTYS versus OHTUVAYRE.
INVELTYS vs OHTUVAYRE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid; modulates inflammatory response by binding to glucocorticoid receptors, altering gene expression and suppressing pro-inflammatory cytokines.
OHTUVAYRE is an antisense oligonucleotide that binds to the survival motor neuron 2 (SMN2) pre-mRNA, altering splicing to increase production of full-length survival motor neuron (SMN) protein.
Instill 1 drop into the affected eye(s) four times daily for 14 days, then taper as clinically indicated.
OHTUVAYRE (vadadustat) is administered orally at a starting dose of 300 mg once daily. The dose may be titrated based on hemoglobin response in increments of 150 mg up to a maximum of 600 mg once daily.
None Documented
None Documented
Approximately 1.5 hours (range 1-2 hours) for the ophthalmic suspension; terminal half-life in systemic circulation is about 3 hours after topical ocular administration.
Terminal elimination half-life is approximately 20 hours (range 15-25 h), supporting once-daily dosing.
Primarily hepatic metabolism with minimal renal excretion (<5% unchanged in urine). Fecal elimination accounts for approximately 20% of the dose.
Primarily renal excretion as unchanged drug: 70-80% in urine, with approximately 20% in feces via biliary elimination.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid